DK1027043T3 - Benzodioxol-, benzofuran-, dihydrobenzofuran- og benzodioxanmelatonerge midler - Google Patents

Benzodioxol-, benzofuran-, dihydrobenzofuran- og benzodioxanmelatonerge midler

Info

Publication number
DK1027043T3
DK1027043T3 DK97952354T DK97952354T DK1027043T3 DK 1027043 T3 DK1027043 T3 DK 1027043T3 DK 97952354 T DK97952354 T DK 97952354T DK 97952354 T DK97952354 T DK 97952354T DK 1027043 T3 DK1027043 T3 DK 1027043T3
Authority
DK
Denmark
Prior art keywords
benzodioxane
benzodioxole
dihydrobenzofuran
benzofuran
melatonergic agents
Prior art date
Application number
DK97952354T
Other languages
Danish (da)
English (en)
Inventor
Ronald J Mattson
Katherine S Takaki
Joseph P Yevich
John D Catt
Graham Johnson
Daniel J Keavy
Michael F Parker
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1027043T3 publication Critical patent/DK1027043T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Polyesters Or Polycarbonates (AREA)
DK97952354T 1996-12-10 1997-12-09 Benzodioxol-, benzofuran-, dihydrobenzofuran- og benzodioxanmelatonerge midler DK1027043T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3268996P 1996-12-10 1996-12-10
EP97952354A EP1027043B1 (en) 1996-12-10 1997-12-09 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents

Publications (1)

Publication Number Publication Date
DK1027043T3 true DK1027043T3 (da) 2005-01-10

Family

ID=21866306

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97952354T DK1027043T3 (da) 1996-12-10 1997-12-09 Benzodioxol-, benzofuran-, dihydrobenzofuran- og benzodioxanmelatonerge midler

Country Status (26)

Country Link
US (3) US5856529A (ko)
EP (1) EP1027043B1 (ko)
JP (1) JP4290765B2 (ko)
KR (1) KR100499106B1 (ko)
CN (1) CN1152679C (ko)
AR (1) AR010346A1 (ko)
AT (1) ATE281833T1 (ko)
AU (1) AU719994B2 (ko)
BR (1) BR9713690B1 (ko)
CA (1) CA2274183C (ko)
CY (1) CY2501B1 (ko)
CZ (1) CZ297673B6 (ko)
DE (1) DE69731562T2 (ko)
DK (1) DK1027043T3 (ko)
ES (1) ES2230626T3 (ko)
HK (1) HK1029947A1 (ko)
HU (1) HU226524B1 (ko)
IL (1) IL129999A (ko)
NO (1) NO321450B1 (ko)
NZ (1) NZ335910A (ko)
PL (1) PL190499B1 (ko)
PT (1) PT1027043E (ko)
RU (1) RU2190609C2 (ko)
TW (1) TW476758B (ko)
WO (1) WO1998025606A1 (ko)
ZA (1) ZA9711051B (ko)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614347D0 (en) * 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
WO1999062515A1 (en) * 1998-06-05 1999-12-09 Bristol-Myers Squibb Company Heterocyclic cis cyclopropane derivatives as melatonergic agents
US6211225B1 (en) * 1999-06-30 2001-04-03 Bristol-Meyers Squibb Heterocyclic aminopyrrolidine derivatives as melatonergic agents
CZ20033037A3 (cs) 2001-05-15 2004-06-16 F. Hoffmann-La Roche Ag Karboxylové kyselinou odvozené od substituovaných oxazolových derivátů pro použití jako PPAR-alfa a -gama aktivátory při léčbě diabetu
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
EP1432696A1 (en) * 2001-10-04 2004-06-30 Wyeth Chroman derivatives as 5-hydroxytryptamine-6 ligands
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
CN100402510C (zh) * 2002-07-03 2008-07-16 霍夫曼-拉罗奇有限公司 噁唑衍生物及其作为胰岛素敏化剂的应用
RU2296754C2 (ru) * 2002-08-30 2007-04-10 Ф.Хоффманн-Ля Рош Аг НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPAR α И PPAR γ
SI1539746T1 (sl) * 2002-09-12 2007-04-30 Hoffmann La Roche Spojine n-substituirane-1h-indol-5-propionske kisline kot agonisti ppar, ki so uporabne za zdravljenje diabetesa
KR100713266B1 (ko) * 2002-11-25 2007-05-04 에프. 호프만-라 로슈 아게 인돌릴 유도체
US7145478B2 (en) * 2002-12-17 2006-12-05 Evolution Robotics, Inc. Systems and methods for controlling a density of visual landmarks in a visual simultaneous localization and mapping system
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
PT2028937E (pt) * 2006-05-22 2015-04-09 Vanda Pharmaceuticals Inc Tratamento por agonista de melatonina
MX2008014840A (es) * 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de trastornos depresivos.
EA200971003A1 (ru) * 2007-04-26 2010-04-30 Такеда Фармасьютикал Компани Лимитед Бициклическое соединение и его фармацевтическое применение
US7964430B2 (en) * 2007-05-23 2011-06-21 Applied Materials, Inc. Silicon layer on a laser transparent conductive oxide layer suitable for use in solar cell applications
WO2009036257A1 (en) * 2007-09-13 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
EP2287159A1 (en) * 2009-07-29 2011-02-23 V.Mane Fils New bicyclic dioxanes, their preparation and their use as organoleptic compounds
BR112013006594B1 (pt) * 2010-09-22 2021-08-17 Eisai R&D Management Co., Ltd Composto ciclopropano antagonista de receptor da orexina e composição farmacêutica
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
ES2646197T3 (es) 2012-01-26 2017-12-12 Vanda Pharmaceuticals Inc. Tratamiento de trastornos del ritmo circadiano
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CN104583178A (zh) 2012-05-18 2015-04-29 万达制药公司 (1r-反)-n-[[2-(2，3-二氢-4-苯并呋喃基)环丙基]甲基]丙酰胺代谢物
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
EP2884275A4 (en) * 2012-07-10 2016-04-13 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF STRESS-RELATED HARNINE CONTINENCE OR MIXED INCONTINENCE AND METHOD FOR SCREENING COMPOUNDS FOR INTRODUCTION TO THIS PHARMACEUTICAL COMPOSITION
WO2014100292A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
WO2015047113A1 (en) * 2013-09-30 2015-04-02 Polfarmex S.A. Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as η1-receptor antagonists
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
WO2015117048A1 (en) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP3470405A1 (en) 2014-02-12 2019-04-17 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon
CN106604726A (zh) 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
CN104327022B (zh) * 2014-10-17 2015-12-02 苏州明锐医药科技有限公司 他司美琼的制备方法
CN104402849B (zh) * 2014-11-11 2016-11-09 苏州莱克施德药业有限公司 他司美琼中间体的新制备工艺
CN106588841B (zh) * 2015-10-19 2019-01-25 富乐马鸿凯（大连）医药有限公司 合成2,3-二氢-1-苯并呋喃-4-甲醛的方法
KR20190008265A (ko) 2016-05-06 2019-01-23 피지션즈 씰, 엘엘씨 발레리안 조성물 및 관련 방법
CN105949153B (zh) * 2016-05-10 2018-03-02 浙江工业大学 一种他司美琼的合成方法
CN107365288A (zh) * 2016-05-12 2017-11-21 浙江京新药业股份有限公司 他司美琼的晶型
US9944616B2 (en) 2016-06-08 2018-04-17 Apotex Inc. Processes for the preparation of Tasimelteon and intermediates thereof
CN106543119B (zh) * 2016-09-22 2019-07-26 浙江工业大学 一种光学纯他司美琼的制备方法
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
WO2018149940A1 (en) 2017-02-17 2018-08-23 Quimica Sintetica, S. A. Process for the preparation of enantiomerically enriched dihydrobenzofurans and intermediate compounds obtained in the process
ES2965488T3 (es) 2017-08-02 2024-04-15 Vanda Pharmaceuticals Inc Uso de tasimelteón para el tratamiento de trastornos afectivos en pacientes mayoritariamente negroafricanos
MX2020009159A (es) 2018-03-04 2020-12-11 Vanda Pharmaceuticals Inc Tratamiento de trastornos con tasimelteon.
WO2020056117A1 (en) * 2018-09-12 2020-03-19 Vanda Pharmaceuticals Inc.. Improving sleep or post-sleep performance
CN114641284A (zh) 2019-06-29 2022-06-17 万带兰制药公司 他司美琼在治疗睡眠异常中的应用
NZ789270A (en) * 2019-12-13 2024-07-05 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2667316B1 (fr) * 1990-10-02 1994-09-16 Roussel Uclaf Nouveaux derives du benzofuranne, leur procede de preparation et leur application comme pesticides.
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
FR2696453B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
FR2725985B1 (fr) * 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
US5596019A (en) * 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
CA2176854A1 (en) * 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
WO1997043272A2 (en) * 1996-05-14 1997-11-20 Glaxo Group Limited Benzofurans and benzopyrans as chronobiological agents

Also Published As

Publication number Publication date
CZ199199A3 (cs) 1999-09-15
CY2501B1 (en) 2005-09-02
PL190499B1 (pl) 2005-12-30
IL129999A0 (en) 2000-02-29
RU2190609C2 (ru) 2002-10-10
CA2274183C (en) 2006-10-24
JP2001505916A (ja) 2001-05-08
US5981571A (en) 1999-11-09
EP1027043B1 (en) 2004-11-10
ATE281833T1 (de) 2004-11-15
AU719994B2 (en) 2000-05-18
JP4290765B2 (ja) 2009-07-08
CN1239886A (zh) 1999-12-29
KR20000069396A (ko) 2000-11-25
BR9713690A (pt) 2000-05-02
CZ297673B6 (cs) 2007-02-28
EP1027043A1 (en) 2000-08-16
BR9713690B1 (pt) 2009-08-11
DE69731562T2 (de) 2005-11-24
PL333950A1 (en) 2000-01-31
NZ335910A (en) 2000-11-24
CA2274183A1 (en) 1998-06-18
ES2230626T3 (es) 2005-05-01
EP1027043A4 (en) 2002-02-20
WO1998025606A1 (en) 1998-06-18
HU226524B1 (en) 2009-03-30
HK1029947A1 (en) 2001-04-20
ZA9711051B (en) 1999-06-09
US6060506A (en) 2000-05-09
HUP0000695A3 (en) 2002-09-30
NO992804D0 (no) 1999-06-09
DE69731562D1 (de) 2004-12-16
KR100499106B1 (ko) 2005-07-01
AR010346A1 (es) 2000-06-07
IL129999A (en) 2004-06-20
NO321450B1 (no) 2006-05-15
AU5598598A (en) 1998-07-03
HUP0000695A2 (hu) 2001-05-28
TW476758B (en) 2002-02-21
CN1152679C (zh) 2004-06-09
US5856529A (en) 1999-01-05
NO992804L (no) 1999-08-09
PT1027043E (pt) 2005-02-28

Similar Documents

Publication Publication Date Title
DK1027043T3 (da) Benzodioxol-, benzofuran-, dihydrobenzofuran- og benzodioxanmelatonerge midler
ATE334125T1 (de) (benzodioxan, benzofuran, oder benzopyran) derivate mit fundic entspannungseigenschaften
PT1173431E (pt) Metodo de preparacao do citalopram
DK0901483T3 (da) Benzofuraner og benzopyraner som kronobiologiske midler
NO982414D0 (no) Ny kombinasjon
ID23872A (id) Komposisi farmasi padat yang mengandung turunan benzofuran
KR950700288A (ko) 5-에이취티4 길항제로서의 벤조피란, 벤조티오피란 및 벤조푸란 유도체(Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists)
DK1437359T3 (da) Hidtil ukendte 3,6-hemiketaler fra 9a-azalidklassen
ATE203528T1 (de) Antineurodegenerativ wirksame 10-aminoaliphatyl- dibenz- b,f oxepine
BR9607698A (pt) Absorvente higiênico composto com formato anatômico
FI962419A0 (fi) Ringoskillator med hoeg hastighet
YU10499A (sh) Supstituisani 1,2,3,4-tetrahidro-2-dibenzofuranamini i 2-aminociklohepta /b/benzofurani
DK1187829T3 (da) Aminoalkylsubstituerede (benzodioxan, benzofuran eller benzopyran) derivater
DE59900853D1 (de) 2,4,6-Trimethyl-4-phenyl -1,3-dioxan
NL1004459A1 (nl) Geluidwerende elementen.
DK0814804T3 (da) Substituerede benzopyraner
KR960036038U (ko) 모자의 장식용구
FI980993A0 (fi) Betoni/teräs-liittorakenteinen leukapalkki
SE9600813D0 (sv) Dynamisk hantel
KR970059516U (ko) 마우스용 패드
SE9603955D0 (sv) Ny generator
SE9603016D0 (sv) Ny generator
FI963442A0 (fi) Laparakenne salibandy- tai vastaava mailaa varten
KR970050425U (ko) 인터버의 케이스
FI964199A0 (fi) Suojarakenne